Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D03WPA
|
|||
Former ID |
DAP000652
|
|||
Drug Name |
Trovafloxacin
|
|||
Synonyms |
TVFX; Trovan; Fluorinated quinolone; Trovafloxacin [INN]; CP 99219; CP99219; CP 99,219; CP-99219;Trovafloxacin (INN); Trovan (TN); Trovan (oral); Turvel (TN); CP-99,219; (1alpha,5alpha,6alpha)-7-(6-Amino-3-azabicyclo[3.1.0]hex-3-yl)-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid; 7-((1R,5S)-6-Amino-3-aza-bicyclo[3.1.0]hex-3-yl)-1-(2,4-difluoro-phenyl)-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid; 7-[(1R,5S)-6-amino-3-azabicyclo[3.1.0]hexan-3-yl]-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid; 7-[(1R,5S,6s)-6-amino-3-azabicyclo[3.1.0]hex-3-yl]-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid; 7-[(1r,5s)-6-amino-3-azabicyclo[3.1.0]hex-3-yl]-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Bacterial infection [ICD-11: 1A00-1C4Z; ICD-10: A00-B99] | Approved | [1] | |
Therapeutic Class |
Antiinfective Agents
|
|||
Company |
Pfizer Pharmaceuticals
|
|||
Structure |
Download2D MOL |
|||
Formula |
C20H15F3N4O3
|
|||
Canonical SMILES |
C1C2C(C2N)CN1C3=C(C=C4C(=O)C(=CN(C4=N3)C5=C(C=C(C=C5)F)F)C(=O)O)F
|
|||
InChI |
1S/C20H15F3N4O3/c21-8-1-2-15(13(22)3-8)27-7-12(20(29)30)17(28)9-4-14(23)19(25-18(9)27)26-5-10-11(6-26)16(10)24/h1-4,7,10-11,16H,5-6,24H2,(H,29,30)/t10-,11+,16?
|
|||
InChIKey |
WVPSKSLAZQPAKQ-SOSAQKQKSA-N
|
|||
CAS Number |
CAS 147059-72-1
|
|||
PubChem Compound ID | ||||
PubChem Substance ID |
9866, 604763, 644006, 14831391, 17187237, 32961437, 43120003, 46508751, 49996898, 50940561, 56312374, 56314400, 57288868, 57314924, 96025337, 96099865, 104234146, 104327073, 104826295, 117509495, 124766049, 126666094, 129640810, 134337942, 135021037, 135029115, 135367547, 137003457, 143130985, 152049315, 160964030, 162793562, 175265560, 179316262, 179678466, 184527292, 223403934, 223403935, 223441011, 223659710, 225068555, 226420920, 226420921, 234609108, 252216525, 252358281
|
|||
ChEBI ID |
CHEBI:9763
|
|||
ADReCS Drug ID | BADD_D02307 ; BADD_D02308 | |||
SuperDrug ATC ID |
J01MA13
|
|||
SuperDrug CAS ID |
cas=147059721
|
Interaction between the Drug and Microbe | Top | |||
---|---|---|---|---|
The Abundace of Studied Microbe(s) Regulated by Drug | ||||
The Order in the Taxonomic Hierarchy of the following Microbe(s): Bacteroidales | ||||
Studied Microbe: Bacteroides fragilis
Show/Hide Hierarchy
|
[2] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experimental Species | Human | Experimental Sample | Faeces | |
Disease or Condition | Healthy | |||
Description | The abundance of Bacteroides fragilis was decreased by Trovafloxacin. | |||
The Order in the Taxonomic Hierarchy of the following Microbe(s): Enterobacterales | ||||
Studied Microbe: Enterobacteriaceae
Show/Hide Hierarchy
|
[2] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experimental Species | Human | Experimental Sample | Faeces | |
Disease or Condition | Healthy | |||
Description | The abundance of Enterobacteriaceae was decreased by Trovafloxacin. | |||
Studied Microbe: Escherichia
Show/Hide Hierarchy
|
[2] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experimental Species | Human | Experimental Sample | Faeces | |
Disease or Condition | Healthy | |||
Description | The abundance of Escherichia was decreased by Trovafloxacin. | |||
The Order in the Taxonomic Hierarchy of the following Microbe(s): Lactobacillales | ||||
Studied Microbe: Enterococcus
Show/Hide Hierarchy
|
[2] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experimental Species | Human | Experimental Sample | Faeces | |
Disease or Condition | Healthy | |||
Description | The abundance of Enterococcus was decreased by Trovafloxacin. |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Bacterial DNA gyrase (Bact gyrase) | Target Info | Modulator | [3] |
References | Top | |||
---|---|---|---|---|
REF 1 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 050762. | |||
REF 2 | Effects of single oral doses of gemifloxacin (320 milligrams) versus trovafloxacin (200 milligrams) on fecal flora in healthy volunteers. Antimicrob Agents Chemother. 2001 Feb;45(2):608-11. | |||
REF 3 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.